Tacrolimus BID + Advagraf QD
Phase 3UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Medication Adherence
Conditions
Medication Adherence
Trial Timeline
Aug 1, 2016 → Aug 1, 2018
NCT ID
NCT02805842About Tacrolimus BID + Advagraf QD
Tacrolimus BID + Advagraf QD is a phase 3 stage product being developed by Astellas Pharma for Medication Adherence. The current trial status is unknown. This product is registered under clinical trial identifier NCT02805842. Target conditions include Medication Adherence.
What happened to similar drugs?
3 of 3 similar drugs in Medication Adherence were approved
Approved (3) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02805842 | Phase 3 | UNKNOWN |
Competing Products
6 competing products in Medication Adherence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DFN-11 Injection | Dr. Reddy's Laboratories | Phase 2 | 24 |
| Advagraf + Prograf | Astellas Pharma | Approved | 39 |
| Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + 0.9% natural saline | Johnson & Johnson | Pre-clinical | 22 |
| TasP using ART regimen as per Benin guidelines + PrEP using Truvada | Gilead Sciences | Approved | 43 |
| ziprasidone | Pfizer | Approved | 43 |
| Levetiracetam | UCB | Phase 2 | 35 |